186 related articles for article (PubMed ID: 34405544)
1. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.
Zhao S; Zhu S; Lei X; Xu D; Shi T; Chen Q; Ren F; Chen G; Huang D; Xu S
Thorac Cancer; 2021 Oct; 12(20):2815-2818. PubMed ID: 34405544
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
4. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
7. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
9. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
10. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
[TBL] [Abstract][Full Text] [Related]
11. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
12. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib.
Ju L; Han M; Su J; Wu C; Dong Z
Cancer Chemother Pharmacol; 2018 Sep; 82(3):561-564. PubMed ID: 30083883
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
15. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
[TBL] [Abstract][Full Text] [Related]
17. A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.
Tachi H; Nishino K; Nakaizumi T; Kuramoto K; Shimizu K; Yamamoto Y; Kobayashi K; Ichimura H; Sakata A; Nawa T
Thorac Cancer; 2020 Jul; 11(7):2063-2066. PubMed ID: 32433811
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib inhibition of
Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
[TBL] [Abstract][Full Text] [Related]
19. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
[TBL] [Abstract][Full Text] [Related]
20. Deepening the Knowledge of
Guaitoli G; Bertolini F; Bettelli S; Manfredini S; Maur M; Trudu L; Aramini B; Masciale V; Grisendi G; Dominici M; Barbieri F
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884672
[No Abstract] [Full Text] [Related]
[Next] [New Search]